Skip to main content

Advertisement

SpringerLink
Log in

The future of pharmacovigilance: a personal view

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Moore N et al (1985) Adverse drug reaction monitoring: doing it the French way. Lancet 2(8463):1056–1058

    Article  PubMed  CAS  Google Scholar 

  2. Royer R (1990) Pharmacovigilance. The French system. Drug Safety 5(Suppl 1):137–140

    Google Scholar 

  3. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. Jama 279(15):1200–1205

    Article  PubMed  CAS  Google Scholar 

  4. Pirmohamed MJS, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329(7456):15–19

    Article  PubMed  Google Scholar 

  5. Medawar C, Hardon A (2004) Medicines out of control? – Antidepressants and the conspiracy of goodwill. Aksant Academic Publishers, Amsterdam, p. 260

    Google Scholar 

  6. Radoilska L, Scott D (2005) Trust in the pharmaceutical industry: a philosophical perspective. University of Cambridge, Cambridge

    Google Scholar 

  7. Nelson KM, Talbert RL (1996) Drug-related hospital admissions. Pharmacotherapy 16(4):701–707

    PubMed  CAS  Google Scholar 

  8. Lindquist M (2003) Seeing and observing in international pharmacovigilance - achievements and prospects in worldwide drug safety. University of Nijmegen, Nijmegen

    Google Scholar 

  9. Norén GN, Bate A, Orre R (2005) A hit-miss model for duplicate detection in the WHO drug safety database. ACM, New York

    Google Scholar 

  10. Norén GA (2007) Statistical methods for knowledge discovery in adverse drug reaction surveillance, in Department of Mathematics. Stockholm Univeristy, Stockholm, p. 41

    Google Scholar 

  11. Bate A (2003) The use of a Bayesian confidence propagation neural network in pharmacovigilance, in Department of Pharmacology and Clinical Neuroscience. Umeå University, Umeå

    Google Scholar 

  12. Edwards I (2005) The WHO World Alliance for Patient Safety: a new challenge or an old one neglected? Drug Safety 28(5):379–386

    Article  PubMed  Google Scholar 

  13. Bowdler J (1997) Effective communications in pharmacovigilance. 1 ed. Communications in Pharmacovigilance, Vol. 1. W Lake Ltd, Birmingham, England, p 89

    Google Scholar 

  14. Adice International Limited (2007) The Erice manifesto: for global reform of the safety of medicines in patient care. Drug Saf 30(3):187–190

    Article  Google Scholar 

  15. Wright A (2002) Dialogue in pharmacovigilance. Communication in pharmacovigilance, ed. W. A. The Uppsala Monitoring Centre, Uppsala

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The WHO Foundation Collaborating Centre for International Drug Monitoring, Stora Torget 3, 75320, Uppsala, Sweden

    I. Ralph Edwards

Authors
  1. I. Ralph Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I. Ralph Edwards.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edwards, I.R. The future of pharmacovigilance: a personal view. Eur J Clin Pharmacol 64, 173–181 (2008). https://doi.org/10.1007/s00228-007-0435-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-007-0435-9

Keywords

Search

Navigation